EP1572902B1
(en)
*
|
2002-02-01 |
2014-06-11 |
Life Technologies Corporation |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
ATE508188T1
(de)
|
2002-02-01 |
2011-05-15 |
Life Technologies Corp |
Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
DK2264172T3
(da)
|
2002-04-05 |
2017-11-27 |
Roche Innovation Ct Copenhagen As |
Oligomerforbindelser til modulering af HIF-1á-ekspression
|
US20040248094A1
(en)
*
|
2002-06-12 |
2004-12-09 |
Ford Lance P. |
Methods and compositions relating to labeled RNA molecules that reduce gene expression
|
US20040219565A1
(en)
|
2002-10-21 |
2004-11-04 |
Sakari Kauppinen |
Oligonucleotides useful for detecting and analyzing nucleic acids of interest
|
DK2284269T3
(en)
|
2002-11-18 |
2017-10-23 |
Roche Innovation Ct Copenhagen As |
Antisense design
|
US7480382B2
(en)
*
|
2003-09-30 |
2009-01-20 |
Microsoft Corporation |
Image file container
|
KR20070006709A
(ko)
|
2003-12-23 |
2007-01-11 |
산타리스 팔마 에이/에스 |
Bcl-2의 조절을 위한 올리고머 화합물
|
EP1833840B9
(en)
|
2004-11-09 |
2010-11-10 |
Santaris Pharma A/S |
Potent lna oligonucleotides for the inhibition of hif-1a
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
EP1959012A3
(en)
*
|
2004-12-29 |
2009-12-30 |
Exiqon A/S |
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs
|
CN101437933B
(zh)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
作为药物靶标的天然反义和非编码的rna转录物
|
DK2666859T3
(en)
*
|
2006-04-03 |
2019-04-08 |
Roche Innovation Ct Copenhagen As |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
|
AU2012216487B2
(en)
*
|
2006-04-03 |
2015-05-14 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
|
CN102851291B
(zh)
*
|
2006-04-03 |
2016-03-09 |
斯特拉有限责任公司 |
包含抗微小rna反义寡核苷酸的药物组合物
|
US20090326042A1
(en)
|
2006-05-05 |
2009-12-31 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating expression of crp
|
CA2666191C
(en)
|
2006-10-09 |
2017-07-11 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of pcsk9
|
EP2410053B2
(en)
|
2006-10-18 |
2020-07-15 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds
|
EA200900741A1
(ru)
*
|
2006-11-27 |
2010-04-30 |
Айзис Фармасьютикалз, Инк. |
Способы лечения гиперхолестеринемии
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
CA2681406A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
RU2015127794A
(ru)
|
2007-03-24 |
2018-12-21 |
Касл Терапьютикс, ЭлЭлСи |
Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
|
WO2008132234A2
(en)
|
2007-05-01 |
2008-11-06 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of beta-catenin
|
CA2686908A1
(en)
|
2007-05-11 |
2008-11-20 |
Enzon Pharmaceuticals, Inc. |
Rna antagonist compounds for the modulation of her3
|
WO2008150729A2
(en)
*
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
WO2009006478A2
(en)
†
|
2007-07-05 |
2009-01-08 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
EP2548962B1
(en)
|
2007-09-19 |
2016-01-13 |
Applied Biosystems, LLC |
Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof
|
ES2463665T3
(es)
|
2007-10-04 |
2014-05-28 |
Stella Aps |
Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
|
US8450290B2
(en)
|
2007-11-26 |
2013-05-28 |
Enzon Pharmaceuticals, Inc. |
Methods for treating androgen receptor dependent disorders including cancers
|
NZ585327A
(en)
|
2007-11-26 |
2012-10-26 |
Santaris Pharma As |
Lna antagonists targeting the androgen receptor
|
JP2011505124A
(ja)
|
2007-12-03 |
2011-02-24 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
Pik3ca発現をモジュレーションするためのrnaアンタゴニスト化合物
|
CA2717792A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
WO2010012667A1
(en)
|
2008-08-01 |
2010-02-04 |
Santaris Pharma A/S |
Micro-rna mediated modulation of colony stimulating factors
|
KR101770435B1
(ko)
*
|
2008-10-03 |
2017-09-05 |
큐알엔에이, 인크. |
자연 안티센스 전사체가 아포리포단백질-a1로 억제에 의해 아포리포단백-a1 관련된 질환의 치료
|
WO2010065671A2
(en)
*
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
JP5773535B2
(ja)
|
2009-04-24 |
2015-09-02 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
インターフェロンに非応答性のhcv患者の治療のための医薬組成物
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
KR101742334B1
(ko)
|
2009-05-08 |
2017-06-01 |
큐알엔에이, 인크. |
Dmd 패밀리에 대한 천연 안티센스 전사체의 억제에 의한 디스트로핀 패밀리 관련된 질환의 치료
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
NZ596608A
(en)
|
2009-06-12 |
2014-01-31 |
Santaris Pharma As |
New potent anti apob antisense compounds
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
CA2768947C
(en)
|
2009-07-24 |
2018-06-19 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
US9234199B2
(en)
|
2009-08-05 |
2016-01-12 |
Curna, Inc. |
Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
|
EP2464731B1
(en)
|
2009-08-11 |
2016-10-05 |
CuRNA, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
EP2480669B1
(en)
|
2009-09-25 |
2017-11-08 |
CuRNA, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
KR20120095397A
(ko)
*
|
2009-10-16 |
2012-08-28 |
글락소 그룹 리미티드 |
Hbv 안티센스 억제제
|
WO2011048125A1
(en)
|
2009-10-20 |
2011-04-28 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
ES2661813T3
(es)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
CA2782373C
(en)
|
2009-12-23 |
2019-03-26 |
Opko Curna, Llc |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
ES2585829T3
(es)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
ES2657969T3
(es)
|
2010-04-02 |
2018-03-07 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el Factor 3 estimulante de colonias (CSF3) por inhibición del transcrito antisentido natural a CSF3
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
CN107988228B
(zh)
|
2010-05-03 |
2022-01-25 |
库尔纳公司 |
通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
CA2799596C
(en)
|
2010-05-26 |
2020-09-22 |
Curna, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
KR102008708B1
(ko)
|
2010-06-23 |
2019-08-08 |
큐알엔에이, 인크. |
전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
|
WO2012007477A1
(en)
|
2010-07-12 |
2012-01-19 |
Santaris Pharma A/S |
Anti hcv oligomers
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
GB201012418D0
(en)
|
2010-07-23 |
2010-09-08 |
Santaris Pharma As |
Process
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
EP2625274B1
(en)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
AU2011326034B2
(en)
|
2010-11-12 |
2016-02-04 |
Roche Innovation Center Copenhagen A/S |
Compositions and methods for treating androgen receptor dependent disorders including cancers
|
AU2011325956B2
(en)
|
2010-11-12 |
2016-07-14 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
CN103459599B
(zh)
|
2010-11-23 |
2017-06-16 |
库尔纳公司 |
通过抑制nanog的天然反义转录物而治疗nanog相关疾病
|
BR112013012319A2
(pt)
|
2010-12-15 |
2019-09-24 |
Miragen Therapeutics |
inibidores de micro rna compreendendo nucleotídeos bloqueados
|
US10017764B2
(en)
|
2011-02-08 |
2018-07-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
US10202599B2
(en)
|
2011-08-11 |
2019-02-12 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
CA2847811C
(en)
|
2011-09-06 |
2019-10-22 |
Curna, Inc. |
Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
|
CA2848753C
(en)
|
2011-09-14 |
2022-07-26 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
JP6177243B2
(ja)
|
2011-10-06 |
2017-08-09 |
ミラゲン セラピューティクス, インコーポレイテッド |
マイクロrnaの調節による全身エネルギーホメオスタシスの制御
|
AU2012322788B2
(en)
|
2011-10-11 |
2018-01-04 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
WO2013173598A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating atp2a2 expression
|
CA2873794A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating smn gene family expression
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
EP2850188A4
(en)
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE MULTIGENIC FAMILY OF HEMOGLOBIN
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
JP2015518713A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
Utrn発現を調節するための組成物及び方法
|
WO2013192576A2
(en)
|
2012-06-21 |
2013-12-27 |
Miragen Therapeutics |
Oligonucleotide-based inhibitors comprising locked nucleic acid motif
|
CA2884608A1
(en)
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
WO2014059353A2
(en)
|
2012-10-11 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
US20150291958A1
(en)
|
2012-11-15 |
2015-10-15 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
KR20150088305A
(ko)
|
2012-11-26 |
2015-07-31 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Fgfr3 발현의 조절을 위한 조성물 및 방법
|
RU2018108405A
(ru)
|
2013-01-30 |
2019-02-26 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты углевода и lna-олигонуклеотида
|
WO2014188001A1
(en)
|
2013-05-24 |
2014-11-27 |
Santaris Pharma A/S |
Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
|
EP3591054A1
(en)
|
2013-06-27 |
2020-01-08 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting pcsk9
|
CN105658797A
(zh)
*
|
2013-08-16 |
2016-06-08 |
Rana医疗有限公司 |
用于调节rna的组合物和方法
|
JP2016534035A
(ja)
|
2013-10-04 |
2016-11-04 |
ラナ セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症を治療するための組成物及び方法
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
US9976143B2
(en)
|
2014-10-03 |
2018-05-22 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
KR20170068469A
(ko)
|
2014-10-10 |
2017-06-19 |
에프. 호프만-라 로슈 아게 |
GalNAc 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
EP3020813A1
(en)
|
2014-11-16 |
2016-05-18 |
Neurovision Pharma GmbH |
Antisense-oligonucleotides as inhibitors of TGF-R signaling
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
SG10201906716QA
(en)
|
2015-01-20 |
2019-08-27 |
Miragen Therapeutics Inc |
Mir-92 inhibitors and uses thereof
|
US20180023081A1
(en)
*
|
2015-02-04 |
2018-01-25 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
ES2893114T3
(es)
|
2015-02-04 |
2022-02-08 |
Bristol Myers Squibb Co |
Métodos para seleccionar moléculas terapéuticas
|
RU2017127609A
(ru)
*
|
2015-02-04 |
2019-03-04 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигомеры тау-белка и их применение
|
WO2016130943A1
(en)
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
US10900036B2
(en)
|
2015-03-17 |
2021-01-26 |
The General Hospital Corporation |
RNA interactome of polycomb repressive complex 1 (PRC1)
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
JP6835826B2
(ja)
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Lna−gプロセス
|
EP3359685A1
(en)
|
2015-10-09 |
2018-08-15 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
ES2852998T3
(es)
|
2015-11-12 |
2021-09-14 |
Hoffmann La Roche |
Oligonucleótidos para inducir la expresión de UBE3A paterno
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
ES2857702T3
(es)
|
2016-03-14 |
2021-09-29 |
Hoffmann La Roche |
Oligonucleótidos para la reducción de la expresión de PD-L1
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
EP3472348B1
(en)
|
2016-06-17 |
2022-06-29 |
F. Hoffmann-La Roche AG |
In vitro nephrotoxicity screening assay
|
JP7012033B2
(ja)
|
2016-06-17 |
2022-02-10 |
エフ.ホフマン-ラ ロシュ アーゲー |
インビトロ腎毒性スクリーニングアッセイ
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
SG10202005885VA
(en)
|
2016-07-01 |
2020-07-29 |
Hoffmann La Roche |
Antisense oligonucleotides for modulating htra1 expression
|
WO2018087200A1
(en)
|
2016-11-11 |
2018-05-17 |
Roche Innovation Center Copenhagen A/S |
Therapeutic oligonucleotides capture and detection
|
WO2018130583A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
US20190345495A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
CN111278991B
(zh)
|
2017-08-25 |
2022-04-01 |
斯托克制药公司 |
用于治疗病况和疾病的反义寡聚体
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
BR122020018622A2
(pt)
|
2017-10-16 |
2021-02-09 |
F. Hoffmann-La Roche Ag |
Molécula de ácido nucleico para redução de papd5 e papd7 de mrna para o tratamento de infecção hepatite b
|
US20200385714A1
(en)
|
2017-12-11 |
2020-12-10 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
US20200378970A1
(en)
|
2017-12-21 |
2020-12-03 |
Hoffmann-La Roche Inc. |
Companion diagnostic for htra1 rna antagonists
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
MX2020005754A
(es)
|
2017-12-22 |
2020-08-20 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
|
KR20200104302A
(ko)
|
2017-12-22 |
2020-09-03 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 티오포스포르아미다이트
|
JP2021511022A
(ja)
|
2018-01-10 |
2021-05-06 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Pias4発現を調節するためのオリゴヌクレオチド
|
JP2021510295A
(ja)
|
2018-01-12 |
2021-04-22 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Gsk3b発現を調節するためのオリゴヌクレオチド
|
SG11202006142PA
(en)
|
2018-01-12 |
2020-07-29 |
Roche Innovation Ct Copenhagen As |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
CA3087966A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
US11447775B2
(en)
|
2018-01-12 |
2022-09-20 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
US20210095276A1
(en)
|
2018-01-17 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
US20210095277A1
(en)
|
2018-01-18 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
CR20200346A
(es)
|
2018-02-09 |
2020-10-19 |
Genentech Inc |
Oligonucleótidos para modular la expresión de tmem106b
|
SG11202007652UA
(en)
|
2018-02-21 |
2020-09-29 |
Bristol Myers Squibb Co |
Camk2d antisense oligonucleotides and uses thereof
|
MX2020010383A
(es)
|
2018-04-05 |
2020-12-10 |
Hoffmann La Roche |
Uso de inhibidores de fubp1 para el tratamiento de infeccion de virus de hepatitis b.
|
EP3790990A1
(en)
|
2018-05-07 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
EP3793685A1
(en)
|
2018-05-18 |
2021-03-24 |
F. Hoffmann-La Roche AG |
Pharmaceutical compositions for treatment of microrna related diseases
|
WO2019224172A1
(en)
|
2018-05-25 |
2019-11-28 |
Roche Innovation Center Copenhagen A/S |
Novel process for making allofuranose from glucofuranose
|
CN112912500A
(zh)
|
2018-06-05 |
2021-06-04 |
豪夫迈·罗氏有限公司 |
用于调节atxn2表达的寡核苷酸
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
EP3818159A1
(en)
|
2018-07-03 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating tau expression
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
CR20210015A
(es)
|
2018-07-13 |
2021-03-22 |
Hoffmann La Roche |
Oligonucleótidos para modular la expresión de rtel 1
|
CA3098267A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
BR112021001756A2
(pt)
|
2018-07-31 |
2021-05-11 |
Roche Innovation Center Copenhagen A/S |
oligonucleotídeos, oligonucleotídeo gapmer, sal farmaceuticamente aceitável, conjugado, composição farmacêutica, usos de um oligonucleotídeo, método para o tratamento ou profilaxia de uma doença, processo para a fabricação de um oligonucleotídeo e invenção
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
WO2020028864A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
WO2020043750A1
(en)
|
2018-08-28 |
2020-03-05 |
Roche Innovation Center Copenhagen A/S |
Neoantigen engineering using splice modulating compounds
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
WO2020089260A1
(en)
|
2018-11-01 |
2020-05-07 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting tia1
|
WO2020104492A1
(en)
|
2018-11-22 |
2020-05-28 |
Roche Innovation Center Copenhagen A/S |
Pyridinium salts as activators in the synthesis of stereodefined oligonucleotides
|
WO2020109344A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Occular administration device for antisense oligonucleotides
|
WO2020109343A1
(en)
|
2018-11-29 |
2020-06-04 |
F. Hoffmann-La Roche Ag |
Combination therapy for treatment of macular degeneration
|
WO2020136125A2
(en)
|
2018-12-21 |
2020-07-02 |
Boehringer Ingelheim International Gmbh |
Antisense oligonucleotides targeting card9
|
JP2022518500A
(ja)
|
2019-01-25 |
2022-03-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
経口薬物送達のための脂質小胞
|
CA3130431A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
KR20210132681A
(ko)
|
2019-02-20 |
2021-11-04 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
신규 포스포라미디트
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
US20220184216A1
(en)
|
2019-03-05 |
2022-06-16 |
Hoffmann-La Roche Inc. |
Intracellular targeting of molecules
|
SG11202109587TA
(en)
|
2019-03-21 |
2021-10-28 |
Codiak Biosciences Inc |
Extracellular vesicle conjugates and uses thereof
|
BR112021019182A2
(pt)
|
2019-04-03 |
2022-05-31 |
Bristol Myers Squibb Co |
Oligonucleotídeos angptl2 antissenso e seus usos
|
EP3947677A1
(en)
|
2019-04-04 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating atxn2 expression
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
WO2020212301A1
(en)
|
2019-04-16 |
2020-10-22 |
Roche Innovation Center Copenhagen A/S |
Novel process for preparing nucleotide p(v) monomers
|
JP2022530537A
(ja)
|
2019-04-30 |
2022-06-29 |
ロシュ イノベーション センター コペンハーゲン エーエス |
レニウムキレート化mag3オリゴヌクレオチドを調製するための新規の方法
|
US11466274B2
(en)
|
2019-05-31 |
2022-10-11 |
Aligos Therapeutics, Inc. |
Modified gapmer oligonucleotides and methods of use
|
JP7155302B2
(ja)
|
2019-06-06 |
2022-10-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
Atxn3を標的とするアンチセンスオリゴヌクレオチド
|
WO2021030780A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting cebp/beta
|
JP2022544935A
(ja)
|
2019-08-14 |
2022-10-24 |
コディアック バイオサイエンシーズ, インコーポレイテッド |
細胞外小胞-nlrp3アンタゴニスト
|
MX2022001767A
(es)
|
2019-08-14 |
2022-06-09 |
Codiak Biosciences Inc |
Construcciones de vesículas-oligonucleótidos antisentido (aso) extracelulares que se dirigen a transductor de señal y activador de la transcripción 6 (stat6).
|
CA3147366A1
(en)
|
2019-08-14 |
2021-02-18 |
Adam T. BOUTIN |
Extracellular vesicles with stat3-antisense oligonucleotides
|
MX2022001770A
(es)
|
2019-08-14 |
2022-05-20 |
Codiak Biosciences Inc |
Vesícula extracelular unida a moléculas y usos de esta.
|
EP4013872A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicles with antisense oligonucleotides targeting kras
|
US20230241089A1
(en)
|
2019-09-25 |
2023-08-03 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
WO2021122921A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
CN114901821A
(zh)
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染症を処置するためのsbds阻害剤の使用
|
JP2023506540A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ. ホフマン-ラ ロシュ エージー. |
B型肝炎ウイルス感染を処置するためのscamp3阻害剤の使用
|
EP4077671A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of saraf inhibitors for treating hepatitis b virus infection
|
EP4077672A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Enhanced oligonucleotides for inhibiting scn9a expression
|
TW202137987A
(zh)
|
2019-12-24 |
2021-10-16 |
瑞士商赫孚孟拉羅股份公司 |
用於治療hbv之靶向hbv的治療性寡核苷酸及tlr7促效劑之醫藥組合
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
CA3173647A1
(en)
|
2020-05-11 |
2021-11-18 |
Isabel AZNAREZ |
Opa1 antisense oligomers for treatment of conditions and diseases
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
JP2023527693A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック, インコーポレイテッド |
神経疾患を治療するための補体成分c1r阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
|
WO2021231211A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
WO2021229036A1
(en)
|
2020-05-13 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Oligonucleotide agonists targeting progranulin
|
CN115884777A
(zh)
|
2020-05-22 |
2023-03-31 |
豪夫迈·罗氏有限公司 |
用于card9的剪接调节的寡核苷酸
|
JP2023529457A
(ja)
|
2020-06-09 |
2023-07-10 |
ロシュ イノベーション センター コペンハーゲン エーエス |
治療用ポリヌクレオチドに使用するためのグアノシン類似体
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
EP4185696A1
(en)
|
2020-07-23 |
2023-05-31 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting rna binding protein sites
|
EP4200419A2
(en)
|
2020-08-21 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Use of a1cf inhibitors for treating hepatitis b virus infection
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
TW202237843A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向atxn3之反義寡核苷酸
|
AR124229A1
(es)
|
2020-12-03 |
2023-03-01 |
Hoffmann La Roche |
Oligonucleótidos antisentido que actúan sobre atxn3
|
JP2023553069A
(ja)
|
2020-12-08 |
2023-12-20 |
エフ. ホフマン-ラ ロシュ アーゲー |
ホスホロジチオエートオリゴヌクレオチドの新規合成
|
JP2023553710A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
プログラニュリンを標的とするためのアンチセンスオリゴヌクレオチド
|
EP4267734A1
(en)
|
2020-12-22 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Oligonucleotides targeting xbp1
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 rtel1 表現之增強型寡核苷酸
|
KR20230147125A
(ko)
|
2021-02-17 |
2023-10-20 |
론자 세일즈 아게 |
세포외 소포-nlrp3 길항제
|
IL305176A
(en)
|
2021-02-17 |
2023-10-01 |
Lonza Sales Ag |
An extracellular vesicle is linked to a biologically active molecule via an optimal linker and an anchored moiety
|
CN117120041A
(zh)
|
2021-04-01 |
2023-11-24 |
隆萨销售股份有限公司 |
胞外囊泡组合物
|
AR126085A1
(es)
|
2021-06-08 |
2023-09-13 |
Hoffmann La Roche |
Agonistas de progranulina de oligonucleótido
|
EP4105328A1
(en)
|
2021-06-15 |
2022-12-21 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
TW202333748A
(zh)
|
2021-07-19 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
|
CA3229305A1
(en)
|
2021-08-16 |
2023-02-23 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
WO2023044094A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023052317A1
(en)
|
2021-09-29 |
2023-04-06 |
F. Hoffmann-La Roche Ag |
Rna editing
|
WO2023078883A1
(en)
|
2021-11-03 |
2023-05-11 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating apolipoprotein e4 expression
|
AU2022384619A1
(en)
|
2021-11-11 |
2024-04-11 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combinations for treatment of hbv
|
WO2023104693A1
(en)
|
2021-12-07 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
WO2023111336A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Oligonucleotide gba agonists
|
WO2023111210A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
WO2023156652A1
(en)
|
2022-02-21 |
2023-08-24 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotide
|
US11931421B2
(en)
|
2022-04-15 |
2024-03-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
WO2023217890A1
(en)
|
2022-05-10 |
2023-11-16 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting cfp-elk1 intergene region
|
WO2023222858A1
(en)
|
2022-05-18 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Improved oligonucleotides targeting rna binding protein sites
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|